What SEC filings does Agios Pharmaceuticals, Inc. submit to the SEC?

Agios Pharmaceuticals, Inc. (AGIO) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about AGIO?

A Form 4 for AGIO discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Agios Pharmaceuticals, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for AGIO?

The 10-K is Agios Pharmaceuticals, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all AGIO SEC filings directly on EDGAR?

You can view all historical Agios Pharmaceuticals, Inc. filings on the SEC EDGAR company page for AGIO. Each filing card on this page links directly to the original SEC document.

How often does Agios Pharmaceuticals, Inc. file with the SEC?

Agios Pharmaceuticals, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling AGIO shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

AGIO SEC Filing News — Agios Pharmaceuticals, Inc.

Latest SEC filings for Agios Pharmaceuticals, Inc. (AGIO) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-08-06.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pedi…

Sector: Healthcare Industry: Biotechnology Market Cap: $2.0B CIK: 1439222

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for AGIO currently lean bearish. Of the 20 filing records displayed, 2 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

AGIO Filing Activity Snapshot 2026-06-23 — 2026-08-06

Insider Transactions (Form 4)

0 buys vs 2 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$914.4K

Gheuens Sarah (Chief Medical Officer) · 2026-08-06

30,000 shares · Form 4

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 16 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 16 filings in this group are Form 4s for Agios Pharmaceuticals, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 16 insider filings shown, the breakdown is 14 compensation award and 2 open-market sale. 2 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×14: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×2: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Form 4 Open-market sale Insider Selling 2026-08-06

AGIO insider Gheuens Sarah (Chief Medical Officer) sold 30,000 shares (~$914.4K)

Gheuens Sarah, listed as Chief Medical Officer at AGIOS PHARMACEUTICALS, INC., reported an open-market sale of 30,000 AGIO shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	30,000	$30.48	$914.4K

Filing: Form 4 (Insider Transaction) Insider: Gheuens Sarah (Chief Medical Officer) Shares: 30,000 Est. Value: $914.4K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-07-10

AGIO insider Form 4 filed for equity award, exercise, or tax withholding

Backstrom Jay T. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	1,447	—	—
`M`	Option exercise derivative · Restricted stock units	1,447	—	—

Filing: Form 4 (Insider Transaction) Insider: Backstrom Jay T. (Director) Shares: 1,447

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-02

AGIO insider Gheuens Sarah (Chief Medical Officer) sold 4,007 shares (~$150.5K)

Gheuens Sarah, listed as Chief Medical Officer at AGIOS PHARMACEUTICALS, INC., reported an open-market sale of 4,007 AGIO shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	8,375	—	—
`S`	Open-market sale	4,007	$37.56	$150.5K
`M`	Option exercise derivative · Restricted stock units	8,375	—	—

Filing: Form 4 (Insider Transaction) Insider: Gheuens Sarah (Chief Medical Officer) Shares: 4,007 Est. Value: $150.5K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-23

AGIO insider Form 4 filed for equity award, exercise, or tax withholding

Ballal Rahul D. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	2,816	—	—
`M`	Option exercise derivative · Restricted stock units	2,816	—	—
`A`	Compensation award derivative · Restricted stock units	2,927	—	—
`A`	Compensation award derivative · Stock options (right to buy)	14,950	—	—

Filing: Form 4 (Insider Transaction) Insider: Ballal Rahul D. (Director) Shares: 2,816

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-23

AGIO insider Form 4 filed for equity award, exercise, or tax withholding

CAPELLO JEFFREY D (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	2,816	—	—
`M`	Option exercise derivative · Restricted stock units	2,816	—	—
`A`	Compensation award derivative · Restricted stock units	2,927	—	—
`A`	Compensation award derivative · Stock options (right to buy)	14,950	—	—

Filing: Form 4 (Insider Transaction) Insider: CAPELLO JEFFREY D (Director) Shares: 2,816

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-23

AGIO insider Form 4 filed for equity award, exercise, or tax withholding

Foster-Cheek Kaye I (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	2,816	—	—
`M`	Option exercise derivative · Restricted stock units	2,816	—	—
`A`	Compensation award derivative · Restricted stock units	2,927	—	—
`A`	Compensation award derivative · Stock options (right to buy)	14,950	—	—

Filing: Form 4 (Insider Transaction) Insider: Foster-Cheek Kaye I (Director) Shares: 2,816

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-23

AGIO insider Form 4 filed for equity award, exercise, or tax withholding

FOUSE JACQUALYN A (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	2,816	—	—
`M`	Option exercise derivative · Restricted stock units	2,816	—	—
`A`	Compensation award derivative · Restricted stock units	2,927	—	—
`A`	Compensation award derivative · Stock options (right to buy)	14,950	—	—

Filing: Form 4 (Insider Transaction) Insider: FOUSE JACQUALYN A (Director) Shares: 2,816

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-23

AGIO insider Form 4 filed for equity award, exercise, or tax withholding

Ho Maykin (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	2,816	—	—
`M`	Option exercise derivative · Restricted stock units	2,816	—	—
`A`	Compensation award derivative · Restricted stock units	2,927	—	—
`A`	Compensation award derivative · Stock options (right to buy)	14,950	—	—

Filing: Form 4 (Insider Transaction) Insider: Ho Maykin (Director) Shares: 2,816

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-23

AGIO insider Form 4 filed for equity award, exercise, or tax withholding

Owen Adams Catherine (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	2,816	—	—
`M`	Option exercise derivative · Restricted stock units	2,816	—	—
`A`	Compensation award derivative · Restricted stock units	2,927	—	—
`A`	Compensation award derivative · Stock options (right to buy)	14,950	—	—

Filing: Form 4 (Insider Transaction) Insider: Owen Adams Catherine (Director) Shares: 2,816

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-23

AGIO insider Form 4 filed for equity award, exercise, or tax withholding

Scadden David (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	2,816	—	—
`M`	Option exercise derivative · Restricted stock units	2,816	—	—
`A`	Compensation award derivative · Restricted stock units	2,927	—	—
`A`	Compensation award derivative · Stock options (right to buy)	14,950	—	—

Filing: Form 4 (Insider Transaction) Insider: Scadden David (Director) Shares: 2,816

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-23

AGIO insider Form 4 filed for equity award, exercise, or tax withholding

Smith Cynthia (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	2,816	—	—
`M`	Option exercise derivative · Restricted stock units	2,816	—	—
`A`	Compensation award derivative · Restricted stock units	2,927	—	—
`A`	Compensation award derivative · Stock options (right to buy)	14,950	—	—

Filing: Form 4 (Insider Transaction) Insider: Smith Cynthia (Director) Shares: 2,816

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-23

AGIO insider Form 4 filed for equity award, exercise, or tax withholding

Viswanadhan Krishnan (Chief Strategy and Operations) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise derivative · Performance share units	3,000	—	—
`A`	Compensation award derivative · Restricted stock units	3,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Viswanadhan Krishnan (Chief Strategy and Operations)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-23

AGIO insider Form 4 filed for equity award, exercise, or tax withholding

Goff Brian (Director, Chief Executive Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise derivative · Performance share units	39,000	—	—
`A`	Compensation award derivative · Restricted stock units	39,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Goff Brian (Director, Chief Executive Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-23

AGIO insider Form 4 filed for equity award, exercise, or tax withholding

Burns James William (Chief Legal Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise derivative · Performance share units	3,000	—	—
`A`	Compensation award derivative · Restricted stock units	3,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Burns James William (Chief Legal Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-23

AGIO insider Form 4 filed for equity award, exercise, or tax withholding

Gheuens Sarah (Chief Medical Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise derivative · Performance share units	3,000	—	—
`A`	Compensation award derivative · Restricted stock units	3,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Gheuens Sarah (Chief Medical Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-23

AGIO insider Form 4 filed for equity award, exercise, or tax withholding

Jones Cecilia (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise derivative · Performance share units	3,000	—	—
`A`	Compensation award derivative · Restricted stock units	3,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Jones Cecilia (Chief Financial Officer)

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 2 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Agios Pharmaceuticals, Inc. has 2 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-08-04

AGIO Form 144 filed for proposed insider sale by SARAH GHEUENS (30,000 shares) ~$914.3K

SARAH GHEUENS filed a Form 144 with the SEC indicating intent to sell AGIO (AGIOS PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: SARAH GHEUENS Shares: 30,000 Est. Value: $914.3K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-07-01

AGIO Form 144 filed for proposed insider sale by Gheuens Sarah (4,007 shares) ~$150.5K

Gheuens Sarah filed a Form 144 with the SEC indicating intent to sell AGIO (AGIOS PHARMACEUTICALS, INC.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Gheuens Sarah Shares: 4,007 Est. Value: $150.5K

View on SEC EDGAR → Open Filing Document →

Material Events 1 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There is 1 in this period for Agios Pharmaceuticals, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-07-30

AGIO filed 8-K — material company event

AGIOS PHARMACEUTICALS, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Agios Pharmaceuticals, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-07-30

AGIO filed Quarterly Report (10-Q)

AGIOS PHARMACEUTICALS, INC. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify Agios Pharmaceuticals, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on AGIO. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — AGIO SEC Filings

More Tools for AGIO

AGIO Full Stock Analysis AGIO Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper AGIO analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the AGIO stock analysis page.

AGIO Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer